Saturday, October 10, 2026

Zoom Stock Went Up By Over 5% So Far Today

ViaNews Editorial Team

November 20, 2020

Zoom Stock Went Up By Over 5% So Far Today
Zoom has been somewhat immune to the crisis with its shares jumping 5.84% to $438.47 at 12:05 EST on Friday. The Nasdaq Stock Market is jumping 0.22% to $11931, on what seems, at the moment, a somewhat positive trend exchanging session on The Nasdaq Stock Market. Zoom's last close was $414.29, below its 52-week high of $588.84. Zoom's sales growth is 316.4% for the current quarter and 287.5% for the next. The company's growth estimates for the current quarter and the next is 744.4% and 333.3%, respectively. Year-on-year quarterly revenue growth grew by 355%, now sitting on 1.35B for the twelve trailing months. Zoom's stock is valued at $438.47 at 12:05 EST, way below its 52-week high of $588.84 and way above its 52-week low of $62.02. Zoom's value is below its 50-day moving average of $478.32 and way above its 200-day moving average of $325.63.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com